



BRAHMS



The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases

Responsabile Scientifico	Antonio Addis, Ursula Kirchmayer
Contatti	tel: +39 6 99722129 fax: +39 6 99722111 e-mail: u.kirchmayer@deplazio.it
Ente Committente	EMA (studio PASS), University of Southern Demark (PI), LEO Pharma (funding)
Durata	2020-2030
Partner	<ul style="list-style-type: none">• University of Southern Denmark• Centre for Pharmacoepidemiology, Unit for Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden• Norwegian Institute of Public Health, Department of Pharmacoepidemiology, Norway• Clinicum/Department of Public Health, University of Helsinki, Finland• Leibniz Institute for Prevention Research and Epidemiology - BIPS GmbH – Bremen, Germany• PHARMO Institute N.V., The Netherlands• Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy• ARS Toscana, Italy• Università di Verona, Italy
Obiettivi / Descrizione Progetto	Il presente studio PASS (post-authorisation safety study) è uno studio osservazionale multicentrico, che mira a valutare un potenziale eccesso di rischio associato con l'uso di brodalumab nel trattamento della psoriasi, in termini di 1) infezioni gravi, 2) tentato suicidio, 3) MACE, 4) tumori maligni.